Literature DB >> 27165622

Neonatal health including congenital malformation risk of 1072 children born after vitrified embryo transfer.

F Belva1, M Bonduelle2, M Roelants3, G Verheyen4, L Van Landuyt4.   

Abstract

STUDY QUESTION: Does vitrification of Day 3 and Day 5 embryos adversely affect birth outcomes of singletons and twins in comparison with peers born after fresh embryo transfer? SUMMARY ANSWER: Neonatal health parameters, including the prevalence of congenital malformations, in singletons and twins born after embryo vitrification are similar to or slightly better than after fresh embryo transfer. WHAT IS ALREADY KNOWN: Although vitrification, rather than slow-freezing, of embryos is routine practice nowadays, convincing evidence regarding the safety for the offspring is sparse. Literature data comprise results from mostly small-sized studies or studies including only Day 3 or only Day 5 vitrified embryo transfers. Overall, better or comparable perinatal outcomes, in terms of higher birthweight and lower risk for small-for-gestational age or for low birthweight, have been reported for singletons born after vitrified embryo transfer compared with fresh embryo transfer. According to the single available study with sufficient sample size, the congenital malformation rate was found to be comparable after vitrified and fresh embryo transfers. STUDY DESIGN, SIZE, DURATION: Data were collected from 960 cycles after transfer of embryos vitrified on Day 3 (n = 457) or Day 5 (n = 503) and from 1644 cycles after fresh embryo transfer on Day 3 (n = 853) or Day 5 (n = 791), performed between 2008 and 2013 at the Centre for Reproductive Medicine of the university hospital UZ Brussel. Outcome measures were neonatal health in terms of birthweight, small-for-gestational age, prematurity rate, perinatal death and major/minor/total malformation rate. PARTICIPANTS/MATERIALS, SETTING,
METHODS: Perinatal health parameters of 11 stillborns and 1061 live borns (827 singletons and 234 twins) in the vitrified group and of 28 stillborns and 1838 live borns (1374 singletons and 464 twins) in the fresh embryo group are reported. Within 3 months after birth, children in the two study groups were assessed clinically with special attention to congenital malformations by a paediatrician blinded to the type of embryo transfer. Data were analysed by multiple linear and logistic regression, adjusted for treatment variables and maternal characteristics. MAIN RESULTS AND THE ROLE OF CHANCE: Mothers to infants in the vitrified group were on average slightly older and more often suffering from pregnancy-related hypertensive disorders than mothers to infants in the fresh transfer group. Singletons born after vitrification showed a higher birthweight standard deviation score (SDS) (-0.4 versus -0.7; 95% confidence interval (CI): 0.0-0.3, P = 0.001) and a lower small-for-gestational age rate (AOR: 0.55; 95% CI: 0.34-0.90) in comparison with peers born after fresh embryo transfer. Preterm birth rate and perinatal death rate were comparable between the two groups (AOR: 0.91; 95% CI: 0.57-1.43 and AOR: 0.97; 95% CI: 0.40-2.36). In twins, neonatal outcomes including birthweight SDS, small-for-gestational age and prematurity rates were comparable in the vitrified and the fresh groups, when adjusted for confounders. Furthermore, the rate of major congenital malformations in live borns was comparable between the vitrified group and the fresh group, both in singletons (2.6 versus 2.8%; AOR: 0.91; 95% CI: 0.47-1.78) and in twins (2.4 versus 2.7%; AOR: 0.51; 95% CI: 0.05-5.72). Also, the total malformation rate in the vitrified group (3.4%; 95% CI: 2.4-4.8) did not differ from the rate in the fresh embryo group (3.9%; 95% CI: 3.1-5.0). The embryonic stage at vitrification or fresh transfer (cleavage-stage embryo or blastocyst) did not influence the birth characteristics or malformation rate. LIMITATIONS, REASONS FOR CAUTION: The main limitation of this study is the rather small twin group. Therefore, the outcome results for twins should be interpreted cautiously. WIDER IMPLICATIONS OF THE
FINDINGS: This study provides evidence that transfer of vitrified Day 3 and Day 5 embryos does not adversely affect the neonatal health of the offspring in comparison with transfer of fresh embryos. Furthermore, neonatal outcomes were not different after transfer of vitrified blastocysts compared with transfer of vitrified cleavage-stage embryos. STUDY FUNDING/COMPETING INTERESTS: Educational grants for establishing and organizing the data collection have come from IBSA, Ferring, Organon, Shering-Plough and Merck. Merck Belgium funded the data collection for outcomes after vitrification between 2012 and 2015. All co-authors, except M.B., declared no conflict of interest. M.B. has received consultancy fees from Organon, Serono Symposia and Merck.
© The Author 2016. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Day 3 embryo; Day 5 embryo; congenital malformations; embryo vitrification; neonatal outcome

Mesh:

Year:  2016        PMID: 27165622     DOI: 10.1093/humrep/dew103

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  22 in total

1.  [Pregnancy and obstetric outcomes of fresh embryo transfer versus frozen-thawed embryo transfer in women below 35 years of age].

Authors:  Ling Sun; Zhi-Heng Chen; Min-Na Yin; Yu Deng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-07-20

2.  Increased pregnancy complications following frozen-thawed embryo transfer during an artificial cycle.

Authors:  Shuang Jing; Xiao Feng Li; Shuoping Zhang; Fei Gong; Guangxiu Lu; Ge Lin
Journal:  J Assist Reprod Genet       Date:  2019-03-29       Impact factor: 3.412

Review 3.  The state of "freeze-for-all" in human ARTs.

Authors:  Natalia Basile; Juan A Garcia-Velasco
Journal:  J Assist Reprod Genet       Date:  2016-09-14       Impact factor: 3.412

Review 4.  Comparison of pregnancy outcomes after vitrification at the cleavage and blastocyst stage: a meta-analysis.

Authors:  MeiFang Zeng; SuQin Su; LiuMing Li
Journal:  J Assist Reprod Genet       Date:  2017-09-22       Impact factor: 3.412

5.  Morula transfer achieves better clinical outcomes than post-thawed cleavage embryos after overnight culture in frozen embryo transfer (FET) cycles.

Authors:  Dongna Hui; Xiaofang Han; Xiaocheng Wang; Wenjuan Ren; Xin Lei; Jianrong Liu; Lina Dong; Hong Li
Journal:  J Assist Reprod Genet       Date:  2020-02-19       Impact factor: 3.412

6.  Is duration of estrogen supplementation associated with clinical outcomes in frozen-thawed autologous single-blastocyst transfer cycles?

Authors:  Xiaofang Li; Wenhao Shi; Yan'e Gao; Juanzi Shi; Na Li; Haiyan Bai
Journal:  J Assist Reprod Genet       Date:  2022-04-07       Impact factor: 3.357

7.  Effect of embryo and blastocyst transfer on the birthweight of live-born singletons from FET cycles.

Authors:  Junshun Fang; Lihua Zhu; Dong Li; Zhipeng Xu; Guijun Yan; Haixiang Sun; Ningyuan Zhang; Linjun Chen
Journal:  J Assist Reprod Genet       Date:  2018-07-20       Impact factor: 3.412

Review 8.  Secretory products of the corpus luteum and preeclampsia.

Authors:  María M Pereira; Monica Mainigi; Jerome F Strauss
Journal:  Hum Reprod Update       Date:  2021-06-22       Impact factor: 15.610

9.  The risk of birth defects with conception by ART.

Authors:  Barbara Luke; Morton B Brown; Ethan Wantman; Nina E Forestieri; Marilyn L Browne; Sarah C Fisher; Mahsa M Yazdy; Mary K Ethen; Mark A Canfield; Stephanie Watkins; Hazel B Nichols; Leslie V Farland; Sergio Oehninger; Kevin J Doody; Michael L Eisenberg; Valerie L Baker
Journal:  Hum Reprod       Date:  2021-01-01       Impact factor: 6.918

Review 10.  Risk of adverse pregnancy and perinatal outcomes after high technology infertility treatment: a comprehensive systematic review.

Authors:  Stefano Palomba; Roy Homburg; Susanna Santagni; Giovanni Battista La Sala; Raoul Orvieto
Journal:  Reprod Biol Endocrinol       Date:  2016-11-04       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.